SEC Form 4 · accession 0001658613-18-000001
Lexaria Bioscience Corp. · LXRP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Edward McKechnie
Director
Period of report
Jan 20, 2010
Accepted (ET)
May 31, 2018 · 4:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348362
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | May 30, 2018 | S | 47,800 | $1.90 | D | 287,938 | D | |
| Common SharesF1 | May 30, 2018 | S | 100 | $1.91 | D | 287,838 | D | |
| Common SharesF1 | May 31, 2018 | S | 2,100 | $1.90 | D | 285,738 | D | |
| Common Shares | holding | — | — | — | 335,738 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options | $1.53 | May 31, 2018 | A | 50,000 | A | May 31, 2018 | May 31, 2023 | Common Shares | 50,000 | 160,000 | D |
| Stock Options | $0.17 | holding | — | — | — | Sep 16, 2015 | Sep 16, 2020 | Common Shares | 110,000 | 110,000 | D |
Explanation of responses
- F1Price in Canadian Dollars